Johnson & Johnson reports positive results for Talvey in combination with Darzalex Faspro, pomalidomide and Tecvayli in the ...
On Friday, Johnson & Johnson (NYSE:JNJ) released updated results from the investigational Phase 1b RedirecTT-1 study ...
10h
Data from the Phase 3 AURIGA study show Darzalex Faspro plus lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly increases MRD-negative conversion rates at ...
An oral session Friday at the International Myeloma Society 21st Annual Meeting & Exposition offered updates for the TRIMM-2 ...
The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab ...
A new drug combination, talquetamab and teclistamab, shows promising results in treating patients with heavily pretreated ...
After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback